GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)

Exclusion Criteria

• •6. Have at least one measurable lesion according to Lugano classification 2014 and FDG-PET was positive.
• •7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• •8. Life expectancy of ≥ 12 weeks.
• •9. Have adequate hematologic and organ function .
• •1. Nodular lymphocytes are non-Hodgkin's lymphoma or gray area lymphoma.
• •2. Central nervous system lymphoma invasion.
• •3. Subjects requiring systemic corticosteroids or other immunosuppressive agents within 14 days prior to screening or during the study period.
• •4. Prior exposure to any anti-PD-1, anti-PD-L1,anti-PD-L2, anti-CD137,anti-CTLA-4 antibody, or any other antibody or drug target for T cell co-stimulatory or checkpoint pathways.
• •5. Known human immunodeficiency virus (HIV), or serologic status reflecting active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
• •6. Subjects with other malignancy within 5 years prior to the first dose of study treatment, except for Cervical carcinoma in situ and Cured basal cell carcinoma of the skin.
• •7. Have received chemotherapy, radiotherapy, molecular-targeted therapy or major surgery within 4 weeks prior to the first dose of study treatmen; Clinically significant AE associated with previous treatment has not returned to baseline or ≤1 (except hair loss).
• •8. Pregnant or breast-feeding women.
• •9. Patients are unsuitable for the study evaluated by investigator.